Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.55 |
| ▸ | SPR | P35270 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917001 | 0.96 | GRM5 (0.50) | GRM5SPRHSD11B1USP2CYP3A4 | |
| SCHEMBL22032412 | 0.80 | GRM5 (0.56) | GRM5SPRHSD11B1USP2CYP3A4 | |
| SCHEMBL31418213 | 0.79 | SPR (0.39) | GRM5SPRHSD11B1CYP3A4CYP1A2 | |
| SCHEMBL21223637 | 0.78 | GRM5 (0.55) | GRM5SPRHSD11B1USP2CYP3A4 | |
| SCHEMBL4072598 | 0.78 | GRM5 (0.59) | GRM5SPRHSD11B1USP2CYP3A4 | |
| SCHEMBL9955820 | 0.78 | ALDH1A1 (0.43) | GRM5SPRUSP2CYP3A4CYP1A2 | |
| SCHEMBL8905402 | 0.78 | GRM5 (0.50) | GRM5SPRHSD11B1CYP3A4CYP2D6 | |
| SCHEMBL346850 | 0.77 | CYP1A2 (0.42) | GRM5SPRHSD11B1USP2CYP1A2 | |
| SCHEMBL20612530 | 0.77 | ALDH1A1 (0.39) | GRM5SPRHSD11B1ALDH1A1CYP2C9 | |
| SCHEMBL12335229 | 0.77 | GRM5 (0.58) | GRM5USP2CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | GRM5 2912/4885SPR 1448/4885HSD11B1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.